Hannu Revitzer

University of Helsinki

Papers

1

Total Citations

18

H-Index

1

About

Hannu Revitzer is a leading figure in the advancement of boron neutron capture therapy (BNCT), a targeted form of radiation oncology. His key research focuses on the clinical translation of BNCT, particularly the transition from nuclear reactor-based neutron sources to compact proton accelerator-based systems. Revitzer’s most impactful contribution is his comprehensive review of the Finnish BNCT experience, which analyzed outcomes for 249 patients treated at Helsinki University Hospital between 1999 and 2012 using the FiR 1 reactor and l-BPA-F as a boron carrier. This work, cited 18 times, provides critical long-term data on efficacy and safety, helping to validate BNCT as a viable treatment for aggressive cancers. By documenting this pioneering clinical series, Revitzer has helped shape the global roadmap for BNCT, demonstrating how historical reactor-based results inform the design of next-generation accelerator facilities. His work bridges decades of clinical practice with emerging technologies, solidifying his role as a key translator of BNCT from experimental therapy to a practical, hospital-based treatment modality.

Research Focus

Key Achievements

1
H-Index
1
Papers
18
Total Citations
18
Avg Citations/Paper
🏆 Most Cited Paper
From Nuclear Reactor-Based to Proton Accelerator-Based Therapy: The Finnish Boron Neutron Capture Therapy Experience
18 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: University of Helsinki

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago